Literature DB >> 2785723

Serum fluoxetine and norfluoxetine concentrations and antidepressant response.

M W Kelly1, P J Perry, S G Holstad, M J Garvey.   

Abstract

A high-performance liquid chromatography assay for fluoxetine and its major metabolite, norfluoxetine, was established. Serum concentrations of the two were measured in 13 depressed outpatients following a 6-week trial of the drug. No significant correlations were obvious between clinical improvement as measured by the Hamilton Rating Scale for Depression and the Clinical Global Impression scores and the serum concentrations of fluoxetine and its major metabolite, norfluoxetine, according to these initial pilot data.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2785723     DOI： 10.1097/00007691-198903000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


  16 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 2.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 3.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 4.  Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.

Authors:  S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

5.  Serotonin reuptake inhibitor, fluoxetine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca2+ sensitivity.

Authors:  P Pacher; Z Ungvari; V Kecskemeti; A Koller
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 6.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

7.  Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.

Authors:  János Magyar; Norbert Szentandrássy; Tamás Bányász; Valéria Kecskeméti; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-26       Impact factor: 3.000

Review 8.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

9.  Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

Authors:  Adrián LLerena; Pedro Dorado; Roland Berecz; Antonio P González; Eva M Peñas-LLedó
Journal:  Eur J Clin Pharmacol       Date:  2004-01-16       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.